title: Management of urological malignancies: Has positron emission tomography/computed tomography made a difference?
abstract: Positron emission tomography/computed tomography (PET/CT) technology has been a significant, but expensive addition to the oncologist's armamentarium. The aim of this review was to determine the clinical utility of PET/CT in urological oncology, its impact on disease outcome and cost-effectiveness. We searched MedLine and peer reviewed journals for all relevant literature available online from the year 2000 until January 2014 regarding the use of PET/CT in the management of urological malignancies. (11)C-choline PET/CT has emerged as a powerful tool for assessment of biochemical relapse in prostate cancer. Use of novel radiotracers like (124)I-girentuximab has shown promise in the diagnosis of clear cell renal carcinoma. Fluorodeoxyglucose PET has a proven role in seminoma for the evaluation of postchemotherapy residual masses and has shown encouraging results when used for detection of metastasis in renal, bladder, and penile cancer. Introduction of novel radiotracers and advanced technology has led to a wider application of PET/CT in urological oncology. However, testicular seminoma aside, its impact on disease outcome and cost-effectiveness still needs to be established.
authors.affiliation: Department of Urology, Christian Medical College, Vellore, Tamil Nadu, India.
authors.forename: Thampi John
authors.initials: TJ
authors.lastname: Nirmal
authors.affiliation: Department of Urology, Christian Medical College, Vellore, Tamil Nadu, India.
authors.forename: Nitin S
authors.initials: NS
authors.lastname: Kekre
keywords: Bladder cancer; penile cancer; positron emission tomography/computed tomography; prostate cancer; renal cell carcinoma; testicular germ cell tumor; urological